Patients with mantle-cell lymphoma (MCL) are commonly treated with a combination regimen comprising rituximab and high-dose cytarabine, followed by autologous stem-cell transplantation (ASCT). In a study led by Steven Le Gouill, post-transplantation maintenance therapy with rituximab has been shown to extend event-free survival (EFS).
In this trial, 299 patients younger than 66 years of age at diagnosis received induction therapy with rituximab, dexamethasone, high-dose cytarabine and a platinum derivative (R-DHAP regimen). The overall and complete response rates after induction were 94% and 41%, respectively.
Subsequently, 257 patients underwent ASCT, and 240 of them were randomly assigned (1:1 ratio) to either rituximab maintenance therapy or observation only. The scheduled 3-year rituximab treatment course was completed by 83 patients. Median follow-up durations were 54.4 months from inclusion, and 50.2 months from randomization.
In the randomized population, median EFS, progression-free survival (PFS) and overall survival (OS) durations were not reached in either group. The 4-year EFS, PFS and OS rates were higher in the rituximab group compared with the observation group (79%, 83% and 89%, versus 61%, 64% and 80%). Neutropenia, the most common grade 3–4 toxicity, was more frequent with rituximab than with observation (41.1%, 15.7% and 12.1% with <6 months, 6–12 months or 12–36 months of maintenance therapy, respectively, versus 26.3%, 0.9% and 2.9%). Indeed, rituximab was discontinued in 9 patients owing to neutropenia and in 16 patients owing to disease progression.
These results show that maintenance therapy with rituximab after R-DHAP and ASCT improves the outcomes of patients with MCL. Whether this maintenance regimen would benefit patients who receive other pre-ASCT combinations of rituximab remains to be determined.
References
Le Gouill, S. et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N. Engl. J. Med. 377, 1250–1260 (2017)
Rights and permissions
About this article
Cite this article
Romero, D. Extended EFS with rituximab. Nat Rev Clin Oncol 14, 714 (2017). https://doi.org/10.1038/nrclinonc.2017.168
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.168